• Preclinical oncology researcher with extensive program management expertise, sound business acumen, and proven track record of delivering actionable results in preclinical drug development and strategic projects in time and on budget.

• Demonstrated leadership skills and a proven ability to forge strong partnerships across highly matrixed organizations and cross-functional teams to effectively interact and communicate across all levels of the organization.

• Hands-on experience to translate novel anti-cancer small molecule-based concepts into clinical product candidates.

1.   Firestone R S, Feng M, Basu I, Peregrina, K, Augenlicht, LH, Schramm VL. Transition state analogue of MTAP extends lifespan of APC^Min/+ mice. Scientific Reports 2021:11:8844. DOI: 10.1038/s41598-021-87734-6. 

2.   Singh S, Gutierrez-Chavez C, Skalina K, Koba W, Basu I, Barry S, Guha C. Acoustic immune priming of radiation therapy eradicates primary tumor and reduces distant metastases in triple-negative murine breast cancer. Cancer Research 2019 July 1(79) (13 Supplement) 3938; DOI: 10.1158/1538-7445.AM2019-3938.

3.      Lazar-Molnar E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine 2017 Mar; 17:30-44. doi: 10.1016/j.ebiom.2017.02.004. Epub 2017 Feb 6.

4.    Quinn TJ, Healy N, Sara A, Maggi E, Claros CS, Kabarriti R, Scandiuzzi L, Liu L, Gorecka J, Adem A, Basu I, Yuan Z, Guha C. Preclinical evaluation of radiation and systemic, RGD-targeted, adenoassociated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma. Cancer Gene Therapy 2017 Jan;24(1):13-19. doi: 10.1038/cgt.2016.70. Epub 2016 Dec 9.

5.   Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 2016 Apr 21;165(3):643-55.

6.     Bandyopadhyay S, Quinn TJ, Scandiuzzi L, Basu, I, Partanen A, Tome, WA, Macian F, Guha C. Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape.  Journal of Immunology 2016 Feb 15:196 (4): 1964-76.

7.    Mani KM, Savage T, Basu I, Scandiuzzi L, Asp P, Guha C. Epigenetic priming and high-dose radiation for enhanced immune response in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics 2016 October, 96(2S), S86-S87.

8.    Brodin NP, Tang J, Skalina K, Quinn T, Basu, I, Guha C, Tome WA. Semiautomatic cone beam CT segmentation of in vivo preclinical subcutaneous tumours provides an efficient non-invasive alternative for tumour volume measurements. British Journal of Radiology 2015 Jun; 88 (1050): 20140776.

9.   Quinn TJ, Healy N, Kabarriti R, Yuan Z, Scandiuzzi L, Adem A, Basu I, Guha C. Immunophenotype of B16-F10 Melanoma after combination therapy with radiation and systemic, RGD-targeted, adenoassociated virus phage-TNF.  International Journal of Radiation Oncology Biology Physics 2014; 90(1): S806-S807.

10.  Agoni L, Basu I, Gupta S, Alfieri A, Gambino A, Goldberg GL, Reddy EP, Guha C. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.  International Journal of Radiation Oncology Biology Physics 2014; 88(5): 1180-1187.

11.  Basu I, Locker J, Cassera MB, Belbin TJ, Merino EF, Dong X, Hemeon I, Evans GB, Guha C, Schramm VL. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5’-methylthioadenosine phosphorylase.  Journal of Biological Chemistry 2011; 286(6): 4902-4911.

12.  Schramm, VL, Gutierrez JA, Cordovano G, Basu I, Guha C, Belbin TJ, Evans GB, Tyler PC, and Furneaux RH. Transition state analogues in quorum sensing and SAM recycling.  Nucleic Acids Symp Ser (Oxf). 2008;(52): 75-6.

13.  Agoni L, Basu I, Reddy EP, Alfieri A and Guha C. Higher efficacy of ON01910.Na as a potent radiosensitizer than cisplatin on human cervical carcinoma cells.  International Journal of Radiation Oncology Biology Physics 72(1), S709-S710, 2008.

14. Agoni L, Basu I, Danish A, Reddy EP, Alfieri A and Guha C. In vitro Comparative Efficacy of ON01910.Na and Cisplatin with Radiation on Cervical Carcinoma Cells.  Journal of Clinical Oncology, 2008 ASCO Annual Proceedings I (May 20 Supplement), 2008.

15. Basu I, Cordovano G, Das I, Belbin T J, Guha C, Schramm VL. A transition state analogue of 5'- methylthioadenosine phosphorylase induces apoptosis in head and neck cancers.  Journal of Biological Chemistry 2007, 282, 21477-21486.

16.  Storck K, Brandwein M, Guha C, Schlecht N, Basu I, Mahmood R, Prystowsky, M and Schramm VL. 5’-methylthioadenosine phosphorylase (MTAP): A potential therapeutic target for upper aerodigestive tract squamous cell carcinomas (UADT-SCC).  Modern Pathology 2007, 20, 230A-230A 1053 Suppl. 2.

17.  Basu I, Guha C and Schramm VL. A small molecule inhibitor of methylthioadenosine phosphorylase (MTAP) for the treatment of human head and neck carcinoma.  International Journal of Radiation Oncology Biology Physics 2005, 63, S377-S377 2248 Suppl. 1.

18.  Wang X, Deng H, Basu I and Liang Zhu. Induction of Androgen Receptor–dependent Apoptosis in Prostate Cancer Cells by the Retinoblastoma Protein.  Cancer Research 2004, 64, 1377-1385.

19. Basu A, Basu I, Chakraborty A, Pal S and Chattopadhyay U. Detection and Purification of a novel 72kDa glycoprotein male breast tumor associated antigen.  International Journal of Cancer 2003,105(3), 377-383.